ALGER GLOBAL FOCUS FUND
|
Schedule of Investments January 31, 2022 (Unaudited) (Continued)
|
COMMON STOCKS—96.8%
|
SHARES
|
VALUE
|
||||||
AUSTRALIA—3.3%
|
||||||||
APPLICATION SOFTWARE—2.0%
|
||||||||
Xero Ltd.*
|
7,450
|
$
|
603,277
|
|||||
HEALTHCARE TECHNOLOGY—1.3%
|
||||||||
Pro Medicus Ltd.
|
11,700
|
377,706
|
||||||
TOTAL AUSTRALIA
|
||||||||
(Cost $751,454)
|
980,983
|
|||||||
CHINA—3.7%
|
||||||||
AUTOMOBILE MANUFACTURERS—2.2%
|
||||||||
BYD Co., Ltd., Cl. H
|
22,414
|
662,945
|
||||||
INTERNET & DIRECT MARKETING RETAIL—1.5%
|
||||||||
JD Health International, Inc.*
|
54,000
|
436,170
|
||||||
TOTAL CHINA
|
||||||||
(Cost $1,060,196)
|
1,099,115
|
|||||||
FRANCE—8.6%
|
||||||||
APPAREL ACCESSORIES & LUXURY GOODS—3.3%
|
||||||||
LVMH Moet Hennessy Louis Vuitton SE
|
1,185
|
973,246
|
||||||
LIFE SCIENCES TOOLS & SERVICES—2.5%
|
7,300
|
732,876
|
||||||
Eurofins Scientific SE
|
||||||||
RESEARCH & CONSULTING SERVICES—2.8%
|
||||||||
Teleperformance
|
2,175
|
819,008
|
||||||
TOTAL FRANCE
|
||||||||
(Cost $1,389,721)
|
2,525,130
|
|||||||
GERMANY—2.7%
|
||||||||
OIL & GAS REFINING & MARKETING—2.7%
|
||||||||
VERBIO Vereinigte BioEnergie AG
|
12,578
|
801,662
|
||||||
(Cost $607,807)
|
||||||||
HONG KONG—3.1%
|
||||||||
APPAREL ACCESSORIES & LUXURY GOODS—3.1%
|
||||||||
Samsonite International SA *
|
430,483
|
899,730
|
||||||
(Cost $468,119)
|
||||||||
INDIA—2.3%
|
||||||||
DIVERSIFIED BANKS—2.3%
|
||||||||
HDFC Bank Ltd.#
|
10,000
|
686,300
|
||||||
(Cost $675,716)
|
||||||||
IRELAND—2.3%
|
||||||||
PACKAGED FOODS & MEATS—2.3%
|
||||||||
Kerry Group PLC, Cl. A
|
5,450
|
686,626
|
||||||
(Cost $642,123)
|
||||||||
ITALY—7.9%
|
||||||||
APPAREL ACCESSORIES & LUXURY GOODS—5.2%
|
||||||||
Moncler SpA
|
14,053
|
901,835
|
||||||
PRADA SpA
|
101,500
|
620,661
|
||||||
|
1,522,496 |
ALGER GLOBAL FOCUS FUND
|
Schedule of Investments January 31, 2022 (Unaudited) (Continued)
|
COMMON STOCKS—96.8% (CONT.)
|
SHARES
|
VALUE
|
||||||
ITALY—7.9% (CONT.)
|
||||||||
AUTOMOBILE MANUFACTURERS—2.7%
Ferrari NV
|
3,450
|
$
|
796,812
|
|||||
TOTAL ITALY
(Cost $1,880,977)
|
2,319,308
|
|||||||
JAPAN—4.7%
|
||||||||
HEALTHCARE SUPPLIES—2.3%
|
||||||||
Hoya Corp.
|
5,100
|
661,337
|
||||||
INDUSTRIAL MACHINERY—2.4%
|
||||||||
FANUC Corp
|
3,600
|
711,925
|
||||||
TOTAL JAPAN
|
||||||||
(Cost $1,500,241)
|
1,373,262
|
|||||||
NETHERLANDS—7.0%
|
||||||||
DATA PROCESSING & OUTSOURCED SERVICES—2.0%
|
||||||||
Adyen NV*
|
290
|
590,068
|
||||||
HEAVY ELECTRICAL EQUIPMENT—2.0%
|
||||||||
Alfen Beheer BV*
|
8,050
|
600,249
|
||||||
SEMICONDUCTOR EQUIPMENT—3.0%
|
||||||||
ASML Holding NV
|
1,291
|
874,309
|
||||||
TOTAL NETHERLANDS
|
||||||||
(Cost $1,992,864)
|
2,064,626
|
|||||||
NORWAY—3.7%
|
||||||||
ENVIRONMENTAL & FACILITIES SERVICES—1.8%
|
||||||||
Aker Carbon Capture ASA*
|
235,219
|
524,948
|
||||||
INDUSTRIAL MACHINERY—1.9%
|
||||||||
AutoStore Holdings Ltd.*,(a)
|
193,771
|
546,788
|
||||||
TOTAL NORWAY
|
||||||||
(Cost $1,356,540)
|
1,071,736
|
|||||||
SPAIN—1.8%
|
||||||||
BIOTECHNOLOGY—1.8%
|
||||||||
Grifols SA#
|
44,000
|
516,560
|
||||||
(Cost $502,296)
|
||||||||
SWITZERLAND—4.2%
|
||||||||
LIFE SCIENCES TOOLS & SERVICES—1.8%
|
||||||||
PolyPeptide Group AG*
|
5,244
|
522,797
|
||||||
SPECIALTY CHEMICALS—2.4%
|
||||||||
Sika AG
|
2,000
|
699,711
|
||||||
TOTAL SWITZERLAND
|
||||||||
(Cost $853,165)
|
1,222,508
|
|||||||
TAIWAN—1.8%
|
||||||||
SEMICONDUCTORS—1.8%
|
||||||||
Taiwan Semiconductor Manufacturing Co., Ltd.#
|
4,300
|
527,309
|
||||||
(Cost $607,700)
|
||||||||
UNITED STATES—39.7%
|
||||||||
APPLICATION SOFTWARE—9.9%
|
||||||||
Adobe, Inc.*
|
1,893
|
1,011,430
|
ALGER GLOBAL FOCUS FUND
|
Schedule of Investments January 31, 2022 (Unaudited) (Continued)
|
COMMON STOCKS—96.8% (CONT.)
|
SHARES
|
VALUE
|
||||||
UNITED STATES—39.7% (CONT.)
|
||||||||
APPLICATION SOFTWARE—9.9% (CONT.)
|
||||||||
Autodesk, Inc.*
|
2,825
|
$
|
705,657
|
|||||
Intuit, Inc.
|
2,150
|
1,193,744
|
||||||
|
2,910,831
|
|||||||
COPPER—3.0%
|
||||||||
Freeport-McMoRan, Inc.
|
24,000
|
893,280
|
||||||
FINANCIAL EXCHANGES & DATA—3.5%
|
||||||||
MSCI, Inc., Cl. A
|
1,900
|
1,018,628
|
||||||
HEALTHCARE EQUIPMENT—2.6%
|
||||||||
Insulet Corp.*
|
3,150
|
781,200
|
||||||
INTERNET & DIRECT MARKETING RETAIL—5.0%
|
||||||||
Amazon.com, Inc.*
|
490
|
1,465,820
|
||||||
IT CONSULTING & OTHER SERVICES—2.1%
|
||||||||
EPAM Systems, Inc.*
|
1,300
|
618,982
|
||||||
OIL & GAS EQUIPMENT & SERVICES—2.9%
|
||||||||
Schlumberger NV
|
21,800
|
851,726
|
||||||
SEMICONDUCTORS—3.4%
|
||||||||
NVIDIA Corp.
|
4,050
|
991,683
|
||||||
SYSTEMS SOFTWARE—7.3%
|
||||||||
Microsoft Corp.
|
6,900
|
2,145,762
|
||||||
TOTAL UNITED STATES
|
||||||||
(Cost $7,464,351)
|
11,677,912
|
|||||||
TOTAL COMMON STOCKS
|
||||||||
(Cost $21,753,270)
|
28,452,767
|
PREFERRED STOCKS—0.0%
|
SHARES
|
VALUE
|
||||||
UNITED STATES—0.0%
|
||||||||
BIOTECHNOLOGY—0.0%
|
||||||||
Prosetta Biosciences, Inc., Series D*,@,(b),(c)
|
33,858
|
–
|
||||||
(Cost $152,361)
|
||||||||
Total Investments
|
||||||||
(Cost $21,905,631)
|
96.8
|
%
|
$
|
28,452,767
|
||||
Affiliated Securities (Cost $152,361)
Unaffiliated Securities (Cost $21,753,270)
|
28,452,767
|
|||||||
Other Assets in Excess of Liabilities
|
3.2
|
%
|
954,295
|
|||||
NET ASSETS
|
100.0
|
%
|
$
|
29,407,062
|
# |
American Depositary Receipts.--
|
(a) |
Pursuant to Securities and Exchange Commission Rule 144A, this security may be sold prior to its maturity only to qualified institutional buyers. This security represents 1.9% of the net
assets of the Fund.
|
(b) |
Security is valued in good faith at fair value determined using significant unobservable inputs pursuant to procedures established by the Board.
|
(c) |
Deemed an affiliate of the Fund in accordance with Section 2(a)(3) of the Investment Company Act of 1940. See Note 5 - Affiliated Securities.
|
* |
Non-income producing security.
|
ALGER GLOBAL FOCUS FUND
|
Schedule of Investments January 31, 2022 (Unaudited) (Continued)
|
Security
|
Acquisition
Date(s)
|
Acquisition
Cost
|
% of net assets (Acquisition Date)
|
Market
Value
|
% of net assets
as of
1/31/2022
|
|||||||||||||
Prosetta Biosciences, Inc., Series D
|
2/6/15
|
$
|
152,361
|
0.40%
|
|
$
|
0
|
0.00%
|
||||||||||
Total
|
$
|
0
|
0.00%
|
ALGER GLOBAL FOCUS FUND
|
Schedule of Investments January 31, 2022 (Unaudited) (Continued)
|
NOTE 1 — General:
|
NOTE 2 — Significant Accounting Policies:
|
ALGER GLOBAL FOCUS FUND
|
Schedule of Investments January 31, 2022 (Unaudited) (Continued)
|
• |
Level 1 – quoted prices in active markets for identical investments
|
• |
Level 2 – significant other observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds, credit risk, etc.)
|
• |
Level 3 – significant unobservable inputs (including the Fund’s own assumptions in determining the fair value of investments)
|
ALGER GLOBAL FOCUS FUND
|
Schedule of Investments January 31, 2022 (Unaudited) (Continued)
|
ALGER GLOBAL FOCUS FUND
|
Schedule of Investments January 31, 2022 (Unaudited) (Continued)
|
NOTE 3 — Fair Value Measurements:
|
Alger Global Focus Fund
|
TOTAL
|
LEVEL 1
|
LEVEL 2
|
LEVEL 3
|
||||||||||||
COMMON STOCKS
|
||||||||||||||||
Consumer Discretionary
|
$
|
6,757,219
|
$
|
2,262,632
|
$
|
4,494,587
|
$
|
—
|
||||||||
Consumer Staples
|
686,626
|
—
|
686,626
|
—
|
||||||||||||
Energy
|
1,653,388
|
851,726
|
801,662
|
—
|
||||||||||||
Financials
|
1,704,928
|
1,704,928
|
—
|
—
|
||||||||||||
Healthcare
|
3,592,476
|
1,297,760
|
2,294,716
|
—
|
||||||||||||
Industrials
|
3,202,918
|
—
|
3,202,918
|
—
|
||||||||||||
Information Technology
|
9,262,221
|
7,194,567
|
2,067,654
|
—
|
||||||||||||
Materials
|
1,592,991
|
893,280
|
699,711
|
—
|
||||||||||||
TOTAL COMMON STOCKS
|
$
|
28,452,767
|
$
|
14,204,893
|
$
|
14,247,874
|
$
|
—
|
||||||||
PREFERRED STOCKS
|
||||||||||||||||
Healthcare
|
—
|
|
—
|
* |
—
|
—
|
*
|
|||||||||
TOTAL INVESTMENTS IN
SECURITIES
|
$
|
28,452,767
|
$
|
14,204,893
|
$
|
14,247,874
|
$
|
—
|
* |
Prosetta Biosciences, Inc. Series D shares are classified as a Level 3 investment and are fair valued at zero as of January 31, 2022.
|
|
FAIR VALUE
MEASUREMENTS
USING SIGNIFICANT
UNOBSERVABLE
INPUTS (LEVEL 3)
|
Alger Global Focus Fund
|
Preferred Stocks
|
|||
Opening balance at November 1, 2021
|
$
|
—
|
*
|
|
Transfers into Level 3
|
—
|
|||
Transfers out of Level 3
|
—
|
|||
Total gains or losses
|
—
|
|||
Included in net realized gain (loss) on investments
|
—
|
|||
Included in net change in unrealized appreciation (depreciation) on investments
|
—
|
|||
Purchases and sales
|
—
|
|||
Purchases
|
—
|
|||
Sales
|
—
|
|||
Closing balance at January 31, 2022
|
—
|
*
|
||
Net change in unrealized appreciation (depreciation) attributable to investments still held at January 31, 2022
|
$
|
—
|
* |
Prosetta Biosciences, Inc. Series D shares are classified as a Level 3 investment and are fair valued at zero as of January 31, 2022.
|
ALGER GLOBAL FOCUS FUND
|
Schedule of Investments January 31, 2022 (Unaudited) (Continued)
|
Fair Value January 31, 2022
|
Valuation
Methodology
|
Unobservable
Input
|
Range/Input
|
Weighted Average Inputs
|
||||||||||
Alger Global Focus Fund
|
||||||||||||||
Preferred Stocks
|
$ |
—
|
*
|
Income
Approach
|
Discount Rate
|
100.00
|
%
|
N/A
|
* |
Prosetta Biosciences, Inc. Series D shares are classified as a Level 3 investment and are fair valued at zero as of January 31, 2022.
|
TOTAL
|
LEVEL 1
|
LEVEL 2
|
LEVEL 3
|
|||||||||||||
Cash, foreign cash and cash equivalents
|
$
|
913,193
|
$
|
6,238
|
$
|
906,955
|
$
|
–
|
NOTE 4 — Derivatives:
|
NOTE 5 — Affiliated Securities:
|
ALGER GLOBAL FOCUS FUND
|
Schedule of Investments January 31, 2022 (Unaudited) (Continued)
|
Security
|
Value at October 31,
2021
|
Purchases/
Conversion
|
Sales/
Conversion
|
Dividend/
Interest
Income
|
Realized Gain (Loss)
|
Net Change
in
Unrealized
App(Dep)
|
Value at
January 31,
2022
|
|||||||||
Alger Global Focus Fund
|
||||||||||||||||
Preferred Stocks
|
||||||||||||||||
Prosetta Biosciences, Inc.,
|
||||||||||||||||
Series D
|
$ |
–
|
* |
$ |
–
|
$ |
–
|
$ |
–
|
$ |
–
|
$ |
–
|
$ |
–
|
* |
Total
|
$ |
–
|
$ |
–
|
$ |
–
|
$ |
–
|
$ |
–
|
$ |
–
|
$ |
–
|
* |
Prosetta Biosciences, Inc. Series D shares are classified as a Level 3 investment and are fair valued at zero as of January 31, 2022.
|